All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
FT516 and FT538 are two induced pluripotent stem cell (iPSC)-derived cell therapies currently under investigation in phase I clinical trials for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). FT516 is an off-the-shelf natural killer cell immunotherapy administered as monotherapy. FT538 is the first CRISPR-edited iPSC-derived therapy, and its investigational new drug (IND) application has recently been cleared by the U.S. Food and Drug Administration (FDA) as a new monotherapy for patients with AML and as a combination therapy with daratumumab for the treatment of multiple myeloma.
Recently, an update with a cutoff date of April 16, 2021, on two phase I dose-escalation studies evaluating FT516 and FT538 as monotherapies to treat patients with R/R AML was published.1
The ongoing phase I dose-escalation study of FT516 resulted in:
For the FT538 study, three patients were enrolled in the first dose cohort of 100 million cells per dose. The results achieved included:
Across these studies, an objective response with complete leukemic blast clearance in the bone marrow was achieved for five of the twelve patients enrolled.
In both trials there were no cases of dose-limiting toxicity, cytokine release syndrome (any grade), immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease. Overall, the interim data suggest that these novel monotherapies could potentially help patients with R/R AML to achieve durable remissions and complete leukemic blast clearance without further therapeutic interventions and with limited side effects.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox